Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Operating Margin (2016 - 2025)

Historic Operating Margin for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to 0.96%.

  • Harvard Bioscience's Operating Margin rose 94900.0% to 0.96% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.55%, marking a year-over-year decrease of 514700.0%. This contributed to the annual value of 6.6% for FY2024, which is 82900.0% down from last year.
  • Per Harvard Bioscience's latest filing, its Operating Margin stood at 0.96% for Q3 2025, which was up 94900.0% from 4.0% recorded in Q2 2025.
  • Harvard Bioscience's 5-year Operating Margin high stood at 13.69% for Q2 2022, and its period low was 228.11% during Q1 2025.
  • Moreover, its 5-year median value for Operating Margin was 0.89% (2021), whereas its average is 14.26%.
  • As far as peak fluctuations go, Harvard Bioscience's Operating Margin soared by 291600bps in 2023, and later crashed by -2188100bps in 2025.
  • Harvard Bioscience's Operating Margin (Quarter) stood at 5.14% in 2021, then plummeted by -131bps to 1.61% in 2022, then surged by 162bps to 1.0% in 2023, then tumbled by -96bps to 0.04% in 2024, then surged by 2036bps to 0.96% in 2025.
  • Its last three reported values are 0.96% in Q3 2025, 4.0% for Q2 2025, and 228.11% during Q1 2025.